Genetic and maternal effects on valproic acid teratogenesis in C57BL/6J and DBA/2J mice.
Valproic acid (VPA) is used worldwide to treat epilepsy, migraine headaches, and bipolar disorder. However, VPA is teratogenic and in utero exposure can lead to congenital malformations. Using inbred C57BL/6J (B6) and DBA/2J (D2) mice, we asked whether genetic variation could play a role in susceptibility to VPA teratogenesis. Whereas B6 fetuses were more susceptible than D2 fetuses to digit and vertebral malformations, D2 fetuses were more susceptible to rib malformations. In a reciprocal cross between B6 and D2, genetically identical F1 mice carried in a B6 mother had a greater percentage of vertebral malformations following prenatal VPA exposure than F1 mice carried in a D2 mother. This reciprocal F1 difference is known as a maternal effect and shows that maternal genotype/uterine environment is an important mediator of VPA teratogenecity. VPA is a histone deacetylase inhibitor, and it is possible that the differential teratogenesis in B6 and D2 is because of strain differences in histone acetylation. We observed strain differences in acetylation of histones H3 and H4 in both embryo and placenta following in utero VPA exposure, but additional studies are needed to determine the significance of these changes in mediating teratogenesis. Our results provide additional support that genetic factors, both maternal and fetal, play a role in VPA teratogenesis. Lines of mice derived from B6 and D2 will be a useful model for elucidating the genetic architecture underlying susceptibility to VPA teratogenesis.
Downing
Chris
C
Institute for Behavioral Genetics, University of Colorado, Boulder, Colorado 80309-0447, USA. cdowning@pharmacy.isu.edu
Biers
Jami
J
Larson
Colin
C
Kimball
Alexi
A
Wright
Hali
H
Ishii
Takamasa
T
Gilliam
David
D
Johnson
Thomas
T
D000014:Abnormalities, Drug-Induced / Q000209:etiology*; D000818:Animals; D000927:Anticonvulsants / Q000633:toxicity*; D015153:Blotting, Western; D004305:Dose-Response Relationship, Drug; D005260:Female; D005838:Genotype; D056572:Histone Deacetylase Inhibitors / Q000633:toxicity; D006655:Histone Deacetylases / Q000235:genetics; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D013045:Species Specificity; D014635:Valproic Acid / Q000633:toxicity*
D000927:Anticonvulsants; D056572:Histone Deacetylase Inhibitors; D014635:Valproic Acid; D006655:Histone Deacetylases
FASEB J. 2005 Jul;19(9):1166-8
15901671
Hum Mol Genet. 2000 Jan 22;9(2):227-36
10607833
Chem Res Toxicol. 2006 Feb;19(2):272-8
16485903
Curr Opin Neurol. 2007 Apr;20(2):175-80
17351488
J Cell Biochem. 2007 Oct 1;102(2):332-40
17661352
Epilepsia. 2009 May;50(5):1237-46
19507301
Exp Biol Med (Maywood). 2008 Aug;233(8):980-8
18480421
Pharmacogenet Genomics. 2005 Nov;15(11):787-800
16220111
Eur J Med Genet. 2007 Nov-Dec;50(6):411-20
17951123
Cell. 2004 Nov 12;119(4):555-66
15537544
Alcohol. 1997 Jul-Aug;14(4):389-95
9209555
Neurol Clin. 2004 Nov;22(4):799-820
15474768
Can Fam Physician. 2006 Apr;52:441-2, 444, 447
16639967
Teratology. 1988 Oct;38(4):313-20
3149038
Toxicol Sci. 2008 Aug;104(2):397-404
18483001
Reprod Toxicol. 1999 Sep-Oct;13(5):353-60
10560583
Neurology. 2002 Aug 27;59(4):630-3
12196666
Environ Health Perspect. 2004 Aug;112(12):1225-35
15345369
Behav Genet. 1999 Jan;29(1):31-9
10371756
Neurotoxicol Teratol. 2006 Sep-Oct;28(5):617-24
16989981
EMBO J. 2001 Dec 17;20(24):6969-78
11742974
Toxicol Appl Pharmacol. 2007 Apr 15;220(2):178-85
17320131
Toxicol Sci. 2007 Aug;98(2):582-8
17517827
Birth Defects Orig Artic Ser. 1996;30(1):401-5
9125345
Epilepsy Res. 2008 Sep;81(1):1-13
18565732
Reprod Toxicol. 2001 Jan-Feb;15(1):43-8
11137377
Birth Defects Res B Dev Reprod Toxicol. 2005 Oct;74(5):392-8
16193500
Eur J Pharmacol. 2008 Jul 28;589(1-3):45-8
18550052
Methods. 2001 Dec;25(4):402-8
11846609
Neurology. 2008 Sep 30;71(14):1109-17
18703463
Am J Med Genet. 2001 Jan 15;98(2):168-75
11223853